Effect of Osimertinib in Non-Small Cell Lung Cancer Patients with Brain Metastases After Progression Following Front-Line EGFR-TKI Therapy

被引：1
|
作者：
Yu, X. [1 ]
Fan, Y. [1 ]
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Osimertinib; Brain metastases; epidermal growth factor receptor tyrosine kinase inhibitor;
D O I：
10.1016/j.jtho.2019.08.815
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-100
引用
收藏
页码：S400 / S400
页数：1
相关论文
共 50 条
  • [1] Continued EGFR-TKI With Concurrent Radiation Therapy to Improve Time to Progression in Patients with Locally Progressive Non-small Cell Lung Cancer After Front-Line EGFR-TKI Treatment
    Sun, J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E724 - E724
  • [2] Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment
    Wang, Y.
    Li, Y.
    Xia, L.
    Niu, K.
    Chen, X.
    Lu, D.
    Kong, R.
    Chen, Z.
    Sun, J.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (03): : 366 - 373
  • [3] Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment
    Y. Wang
    Y. Li
    L. Xia
    K. Niu
    X. Chen
    D. Lu
    R. Kong
    Z. Chen
    J. Sun
    [J]. Clinical and Translational Oncology, 2018, 20 : 366 - 373
  • [4] EGFR-TKI Therapy Prolongs Survival In Non-small Cell Lung Cancer Patients With Brain Metastases or Bone Metastases
    Hui, L.
    Xiaomei, G.
    Wei, J.
    Chunxue, B.
    Zhaochong, Z.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S621 - S621
  • [5] Effect of EGFR-TKI targeted therapy in patients with advanced non-small cell lung cancer
    Yan, Meihao
    Chen, Shanshan
    Fan, Hongtao
    Hong, Yuancheng
    Huang, Wencheng
    Lin, Zhimin
    Lai, Zhangchao
    Hong, Liyue
    [J]. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (11): : 7916 - 7923
  • [6] Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
    Guo-Hao Xia
    Yun Zeng
    Ying Fang
    Shao-Rong Yu
    Li Wang
    Mei-Qi Shi
    Wei-Li Sun
    Xin-En Huang
    Jia Chen
    Ji- Feng Feng
    [J]. Cancer Biology & Medicine, 2014, (04) : 270 - 276
  • [7] Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
    Guo-Hao Xia
    Yun Zeng
    Ying Fang
    Shao-Rong Yu
    Li Wang
    Mei-Qi Shi
    Wei-Li Sun
    Xin-En Huang
    Jia Chen
    Ji- Feng Feng
    [J]. Cancer Biology & Medicine, 2014, 11 (04) : 270 - 276
  • [8] Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer
    Grant, Christopher
    Nagasaka, Misako
    [J]. CANCER TREATMENT REVIEWS, 2024, 126
  • [9] Icotinib, an EGFR-TKI, for the treatment of brain metastases in non-small cell lung cancer:a retrospective study
    Qunhui Wang
    Hua Zheng
    Ying Hu
    Baohua Lu
    Fanbin Hu
    Hongmei Zhang
    Baolan Li
    [J]. Oncology and Translational Medicine, 2016, 2 (06) : 268 - 274
  • [10] Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy
    Wu, Bin
    Gu, Xiaohua
    Zhang, Qiang
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 184 - 193
12345